Mol Cell:靶向SRPK1酶的抗癌药物

2012-06-25 Beyond 生物谷

近日,加州大学圣地亚哥医学院的研究人员发现一种新的专门调控RNA剪接的信号转导通路,RNA剪接是指从DNA模板链转录出的最初转录产物中除去内含子,并将外显子连接起来形成一个连续的RNA分子的过程。这一发现发表在2012年6月27日的Molecular Cell杂志上,该研究提示新发现的通路可能是一个新的抗癌药物作用环节。 早期研究证实SRPK1与癌症和其它人类疾病有关。例如SRPK1在调节血

近日,加州大学圣地亚哥医学院的研究人员发现一种新的专门调控RNA剪接的信号转导通路,RNA剪接是指从DNA模板链转录出的最初转录产物中除去内含子,并将外显子连接起来形成一个连续的RNA分子的过程。这一发现发表在2012年6月27日的Molecular Cell杂志上,该研究提示新发现的通路可能是一个新的抗癌药物作用环节。

早期研究证实SRPK1与癌症和其它人类疾病有关。例如SRPK1在调节血管内皮生长因子或血管内皮生长因子刺激血液肿瘤血管生长过程中起着关键作用。在许多癌症如肾脏、乳腺癌肺癌和胰腺癌等中SRPK1都被证实表达失调。

Fu和他的同事在这项新的研究中,发现了SRPK1存在于一个重要的细胞信号转导通路中,SRPK1在PI3K-Akt通路中发挥核心作用。
 
研究人员认为SRPK是疾病干预和治疗的一大新靶标。因为其核心作用,并且易被控制,抑制其活性可以有效抑制血管形成。

doi:10.1016/j.molcel.2012.05.014
PMC:
PMID:

The Akt-SRPK-SR Axis Constitutes a Major Pathway in Transducing EGF Signaling to Regulate Alternative Splicing in the Nucleus

Zhihong Zhou, Jinsong Qiu, Wen Liu, Yu Zhou, Ryan M. Plocinik, Hairi Li, Qidong Hu, Gourisanker Ghosh, Joseph A. Adams, Michael G. Rosenfeld, Xiang-Dong Fu

Pre-mRNA splicing is regulated by developmental and environmental cues, but little is known about how specific signals are transduced in mammalian cells to regulate this critical gene expression step. Here, we report massive reprogramming of alternative splicing in response to EGF signaling. By blocking individual branches in EGF signaling, we found that Akt activation plays a major role, while other branches, such as the JAK/STAT and ERK pathways, make minor contributions to EGF-induced splicing. Activated Akt next branches to SR protein-specific kinases, rather than mTOR, by inducing SRPK autophosphorylation that switches the splicing kinases from Hsp70- to Hsp90-containing complexes. This leads to enhanced SRPK nuclear translocation and SR protein phosphorylation. These findings reveal a major signal transduction pathway for regulated splicing and place SRPKs in a central position in the pathway, consistent with their reputed roles in a large number of human cancers.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1868538, encodeId=3b7118685382f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 20 13:04:00 CST 2013, time=2013-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958770, encodeId=11861958e70a2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jul 26 19:04:00 CST 2012, time=2012-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308183, encodeId=565d13081831f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314572, encodeId=defb13145e29b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1868538, encodeId=3b7118685382f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 20 13:04:00 CST 2013, time=2013-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958770, encodeId=11861958e70a2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jul 26 19:04:00 CST 2012, time=2012-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308183, encodeId=565d13081831f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314572, encodeId=defb13145e29b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
    2012-07-26 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1868538, encodeId=3b7118685382f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 20 13:04:00 CST 2013, time=2013-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958770, encodeId=11861958e70a2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jul 26 19:04:00 CST 2012, time=2012-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308183, encodeId=565d13081831f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314572, encodeId=defb13145e29b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1868538, encodeId=3b7118685382f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 20 13:04:00 CST 2013, time=2013-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958770, encodeId=11861958e70a2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jul 26 19:04:00 CST 2012, time=2012-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308183, encodeId=565d13081831f, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314572, encodeId=defb13145e29b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 27 13:04:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
    2012-06-27 sunylz

相关资讯

Onyx公司Kyprolis获FDA肿瘤药物咨询委员会支持

6月20日,Onyx制药公司宣布,FDA肿瘤药物咨询委员会(ODAC)经过效益风险评估,以11:0投票结果决定,支持Kyprolis(Carfilzomib)用于治疗复发/难治性多发性骨髓瘤患者,这类患者此前至少经过包括蛋白酶抑制剂及免疫调节剂的两种疗法。 Onyx称,Kyprolis用于多发性骨髓瘤的研发横跨多种治疗方法。 根据处方药使用者费用法案(Prescription Drug Use

噬菌体展示技术筛选出与宫颈癌细胞HeLa结合短肽

  最近,南华大学肿瘤研究所的研究人员的一项研究显示,利用噬菌体展示技术筛选出与宫颈癌细胞HeLa特异性结合的短肽,进一步与化疗药物结合,为宫颈癌靶向治疗提供新的方法。该研究发表于2012年第3期《中国癌症杂志》。   该研究旨在利用噬菌体体内展示技术筛选及鉴定宫颈癌特异性结合肽,将有可能成为化疗药物的靶向载体,为宫颈癌靶向药物治疗奠定基础。   何晓娟等研究人员体外培养宫颈癌HeLa细胞接种

Cancer Cell:抑制GM-CSF或成胰腺癌治疗新方法

近日,一项发表在Cancer Cell杂志上的研究论文证实:胰腺癌细胞产生一种蛋白质,吸引人体免疫细胞,帮助癌细胞生长。研究还表明阻断该蛋白可能是一种有效的治疗胰腺癌手段。 胰腺癌(pancreatic carcinoma),是胰脏出现的癌症,其恶性肿瘤会在患者的胰脏生长。通常认为胰腺癌是常见肿瘤中恶性程度最高,也是死亡率最高的。40~70岁多见,男性多于女性。近年来发病率有增高趋势。 研究人

PNAS:EVI1促进癌症发展和肿瘤浸润的机制

25年前EVI1基因被发现以来,后续研究证实该转录因子在许多不同类型的癌症包括乳腺癌,前列腺癌和结肠癌、白血病等中都存在。例如在美国,NanoOncology公司已开始开发阻断这种基因的药物。然而只有极少数的EVI1下游靶基因是已知的。 近日,A*STAR研究所分子与细胞生物学教授Emilie Bard-Chapeau等人使用系统生物学的方法,确定了EVI1控制的肿瘤相关基因。这一发现可能导致出

Cancer Res.:VEGF在肿瘤中的非促血管生成活性

据6月15日,Cancer Research杂志在线报道,血管内皮生长因子在肿瘤恶性进展过程中所发挥的不仅是促血管生成功能。 血管内皮生长因子/血管通透性因子(VEGF / VPF或VEGF-A)是肿瘤血管生成的关键驱动力,也是治疗恶性肿瘤的重要治疗靶点。然而,很少有研究工作涉及VEGF不依赖于其促血管生成活性的那部分功能。 该研究表明,由肿瘤细胞产生的血管内皮生长因子以自分泌方式,通过与血管

Nat Genetics:胚胎发育期的遗传组成或引发成年后肿瘤的发生

近日,刊登在国际著名杂志Nature Genetics上的一项研究表明,胚胎期机体的遗传组成(基因组成)或许会引发成年后肿瘤的出现。一个细胞可以分裂为两个具有相同特征、相同遗传物质的细胞之后;基因中的遗传突变会在胚胎发育的过程中发生,而且在细胞分裂的过程中,这种突变会被传递到子代细胞中,结果一个个体中细胞会发生不同的遗传突变,这种现象被成为镶嵌现象,与很多癌症直接相关,但是目前科学界对于这种遗传突